Persisting burden and challenges of rheumatic heart disease.


Journal

European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263

Informations de publication

Date de publication:
07 09 2021
Historique:
received: 16 03 2021
revised: 02 05 2021
accepted: 13 06 2021
pubmed: 16 7 2021
medline: 12 10 2021
entrez: 15 7 2021
Statut: ppublish

Résumé

Rheumatic heart disease (RHD) is the result of episodes of acute rheumatic fever with valvular (and other cardiac) damage caused by an abnormal immune response to group A streptococcal infections, usually during childhood and adolescence. As a result of improved living conditions and the introduction of penicillin, RHD was almost eradicated in the developed world by the 1980s. However, being a disease of poverty, its burden remains disproportionately high in the developing world, despite being a fundamentally preventable disease. Rheumatic heart disease generates relatively little attention from the medical and science communities, in contrast to other common infectious problems (such as malaria, HIV, tuberculosis), despite the major cardiovascular morbidity/mortality burden imposed by RHD. This relative neglect and paucity of funding have probably contributed to limited fundamental medical advances in this field for over 50 years. Given the importance of prevention before the onset of major valvular damage, the main challenges for RHD prevention are improving social circumstances, early diagnosis, and effective delivery of antibiotic prophylaxis. Early identification through ultrasound of silent, subclinical rheumatic valve lesions could provide an opportunity for early intervention. Simple echocardiographic diagnostic criteria and appropriately trained personnel can be valuable aids in large-scale public health efforts. In addition, a better understanding of the immunogenic determinants of the disease may provide potential routes to vaccine development and other novel therapies.

Identifiants

pubmed: 34263296
pii: 6321664
doi: 10.1093/eurheartj/ehab407
doi:

Substances chimiques

Penicillins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3338-3348

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

Auteurs

Eloi Marijon (E)

University of Paris, PARCC, INSERM, Global Health Unit, Paris F-75015, France.
Cardiology Department, European Georges Pompidou Hospital, Paris, France.

Ana Mocumbi (A)

Faculty of Medicine, Universidade Eduardo Mondlane, Maputo, Mozambique.
Instituto Nacional de Saúde, Marracuene, Mozambique.

Kumar Narayanan (K)

University of Paris, PARCC, INSERM, Global Health Unit, Paris F-75015, France.
Medicover Hospitals, Hyderabad, India.

Xavier Jouven (X)

University of Paris, PARCC, INSERM, Global Health Unit, Paris F-75015, France.
Cardiology Department, European Georges Pompidou Hospital, Paris, France.

David S Celermajer (DS)

Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH